Educational guide

Gut Microbe Molecule Reduces Inflammation and Improves Blood Sugar Control

Trimethylamine (TMA), a molecule produced from dietary choline by gut bacteria, has been shown to block a key immune pathway and improve blood sugar control. This microbial molecule may provide a surprising boost in the fight against insulin resistance and typ

Written by Peptide Therapy Guide Editorial TeamPublished September 9, 2026

For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

“This shows how nutrition and our gut microbes can work together by producing molecules that fight inflammation and improve metabolic health,” said Patrice Cani, PhD, professor of Physiology, Metabolism and Nutrition at the Louvain Drug Research Institute (LDRI) of the University of Louvain, Belgium and visiting professor at Imperial College London.

This work appears in Nature Metabolism in the paper, “Inhibition of IRAK4 by microbial trimethylamine blunts metabolic inflammation and ameliorates glycemic control.”

Two decades ago, Cani discovered that a high-fat diet leads to the presence of bacterial components in the body, which activates the immune system and triggers inflammation, eventually causing insulin resistance in diabetic individuals.

Now, a collaborative team has uncovered how to counter this process. They observed that TMA, produced by gut bacteria from the natural nutrient choline—which is found in certain foods—can improve blood-sugar control.

TMA does this by acting as a natural inhibitor of the IRAK4 protein—a key component of the immune system. Normally, when exposed to a high-fat diet, IRAK4 triggers inflammation to signal dietary imbalance. With constant overload (as seen in type 2 diabetes), IRAK4 overreacts, causing cascading inflammation that drives insulin resistance.

By combining human cell models, mouse studies, and molecular-target screening, the team discovered that TMA can bind directly to IRAK4 and block its activity. The direct effect is a reduction in fat-induced inflammation and a restoration of insulin sensitivity. In essence, it reprograms the negative metabolic responses caused by poor diet. Even more striking: the molecule can prevent sepsis-induced mortality in mice by blocking widespread inflammation.

The team also observed that genetically deleting IRAK4 or blocking it pharmacologically reproduced the beneficial effects of the bacterial metabolite. This opens new therapeutic avenues for diabetes, using the target IRAK4, that is already validated within the pharmaceutical industry.

“This flips the narrative,” said Marc-Emmanuel Dumas, PhD, chair in Systems Medicine and head of the Division of Systems Medicine in the Department of Metabolism, Digestion and Reproduction at Imperial College London & CNRS. “We’ve shown that a molecule from our gut microbes can actually protect against the harmful effects of a poor diet through a new mechanism. It’s a new way of thinking about how the microbiome influences our health.”

With more than 500 million people worldwide affected by diabetes, identifying TMA as a microbial signal that modulates immunity could pave the way for new treatments. Nutritional strategies or drugs designed to boost TMA production may offer a new approach to combating insulin resistance and its complications.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗

02How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Related questions

Peptide Therapy Guide Editorial Team

Potential Leukemia Drug Target Found in Epigenetic Protein

Protein Interactions May Now Be Defined in a Quick and Efficient Manner

Mosquitoes Sense Bed Net Insecticides through Their Legs

Cancer Drug Discovery’s “RASzle-Dazzle”